New Data Network Seeks to Provide Much-Needed Info on GLP-1s

OMNY Health has launched a data network to address unanswered questions about GLP-1 drugs and their impact on patients. The network provides data from over 645,000 patients, and will benefit clinical trials with diverse populations, informing decisions on medication use. The data network was recently used to conduct studies on pediatric use of GLP-1s, and how social factors influence health outcomes of patients on the drugs.